home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login »

people

The CRG investment team leverages more than 175 years of collective and complementary experience across healthcare, private equity, capital markets, and operations to deliver the most innovative structures to meet the capital needs of our financing partners.

Collapse
Charles W. Tate is Chairman and Founder of CRG. He has over 40 years’ experience in investment banking, merchant banking, and private equity.

Charles Tate

Chairman and Founder

Charles W. Tate is Chairman and Founder of CRG. He has over 40 years’ experience in investment banking, merchant banking, and private equity. Prior to forming CRG, Mr. Tate was a Partner and Member of the Management Committee of Hicks, Muse, Tate & Furst Incorporated from 1991 until June 2002. After starting his career at Bank of America in New York, he worked at Morgan Stanley & Co. for 19 years, mostly as a Managing Director in the Mergers and Acquisitions Department.

 

Presently, Mr. Tate is Chair and Director of the Board of Directors for The Welch Foundation.  He is also a Life Member of The University of Texas Development Board and a Senior Member of The University Cancer Foundation Board of Visitors for M.D. Anderson Cancer Center and previously was a member of the Board of Visitors Executive Committee.  He also previously served as Chairman of The University of Texas Department of Biomedical Engineering External Advisory Committee, The University of Texas System Chancellor’s Technology Commercialization Advisory Cabinet and The University of Texas at Austin Office of the President Committee on Business Productivity and was Chairman of its Subcommittee on Technology Commercialization.

 

Mr. Tate received his B.B.A. from The University of Texas at Austin in 1968. He was inducted into The University of Texas at Austin McCombs School of Business Hall of Fame in 2003, was named Distinguished Alumnus of The University of Texas in 2007 and also received The University of Texas at Austin 2011-2012 Presidential Citation in recognition of his leadership, sustained commitment, and service to The University.

 

Additionally, Mr. Tate received his M.B.A. from Columbia University Graduate School of Business in 1972 and has been a Member of its Board of Overseers since 2001. 

Collapse
Nate Hukill is the President of CRG and Chairman of CRG’s investment committee and opened the firm’s Boulder office. Mr. Hukill joined CRG in 2009, bringing more than 16 years of...

Nate Hukill

President and Chairman of the Investment Committee

Nate Hukill is the President of CRG and Chairman of CRG’s investment committee and opened the firm’s Boulder office. Mr. Hukill joined CRG in 2009, bringing more than 16 years of investing experience. Prior to joining CRG, Mr. Hukill was a Portfolio Manager at Highland Capital, where he invested and managed approximately $4.5 billion in the healthcare, consumer products, and technology sectors. Mr. Hukill primarily focused on fixed income healthcare investments with superior risk-adjusted returns. Beginning in 2005, Mr. Hukill built a Royalty Bond portfolio with $348 million of invested capital, becoming one of the largest and most influential Royalty Bond investors in the industry. Before Highland Capital, Mr. Hukill co-founded a pharmaceutical-focused enterprise software company called OpenQ, Inc. He started his career as a credit investor at Salomon Smith Barney where he managed a portfolio of approximately $800 million.

 

Mr. Hukill graduated Phi Beta Kappa, summa cum laude from the University of Colorado at Boulder in 1999 with a Bachelor of Science in business administration. He received an M.B.A. from the Darden Graduate School of Business at the University of Virginia in 2005. Mr. Hukill is a former professional cyclist, who competed professionally in both North America and Europe, including more than 30 first-place finishes. He previously was a member of the Board of Directors for Epocal, Inc., Complete Genomics, and OpenQ.

 

Boards and Service

 

  • 2014 to Present – AFT Pharmaceuticals, Board of Directors
  • 2007 to 2009 – Epocal, Inc., Board of Directors
  • 2007 to 2009 – Complete Genomics, Board of Directors
  • 2003 to 2005 – OpenQ, Board of Directors
Collapse
Luke Düster has more than 16 years of experience as both an advisor and investor in high growth companies. Since joining CRG in 2009, Mr. Düster has helped finance healthcare...

Luke Düster

Managing Director

Luke Düster has more than 16 years of experience as both an advisor and investor in high growth companies.  Since joining CRG in 2009, Mr. Düster has helped finance healthcare companies across a wide range of product technologies and therapeutic areas.  He has led investments in companies such as TriVascular, Tandem Diabetes, Nevro Corp., Astute Medical, Good Start Genetics, Nanostring Technologies and others.  Prior to CRG, Mr. Düster was a Vice President at Harris Williams & Co., where he advised private equity and corporate clients across a broad range of M&A assignments.  Mr. Düster also held investment banking roles at the Wallach Company, a regional investment banking boutique, and at the Nord Companies, a healthcare advisory firm.

 

Mr. Düster received a bachelor’s degree from the University of Colorado at Boulder in 1997, where he graduated summa cum laude. He received an MBA with honors from the Wharton School at the University of Pennsylvania in 2004.

Collapse
Michael Weinmann joined CRG in 2009 and has 15 years of capital markets and investing experience. Mr. Weinmann is a member of CRG’s investment committee and opened the firm’s New...

Mike Weinmann

Managing Director

Michael Weinmann joined CRG in 2009 and has 15 years of capital markets and investing experience. Mr. Weinmann is a member of CRG’s investment committee and opened the firm’s New York office. Previously, Mr. Weinmann worked as an Executive Director in Morgan Stanley’s Global Capital Markets division, specializing in structured debt financings and intellectual property monetizations. Mr. Weinmann was a co-developer of the Pharmaceutical Royalty Monetization Asset (Royalty Bond) product and sourced, structured and marketed the industry’s first 14 Royalty Bond transactions. Prior to joining CRG, Mr. Weinmann was responsible for $3.3 billion of healthcare royalty monetizations, including 14 Royalty Bonds and 3 Traditional Royalty Purchases. He joined Morgan Stanley in 1999 and had a leading role in the structuring of debt financings involving pharmaceutical royalties, infrastructure assets, aircraft, rolling stock, ships, power generation facilities, and real estate. 

 

Mr. Weinmann received a Bachelor of Science in chemical engineering in 1999 from the Johns Hopkins University, graduating first in a class of 770.

 

Boards and Service

 

  • 2014 to Present – AFT Pharmaceuticals, Board Observer
  • 2010 to Present – Johns Hopkins Homewood Technology Commercialization, Advisory Board
Collapse
David Carter joined CRG in 2003 and has more than 20 years of investment experience. Prior to joining CRG, Mr. Carter was a Partner at Palestra Capital, a New York-based hedge fund,...

David Carter

Managing Director

David Carter joined CRG in 2003 and has more than 20 years of investment experience. Prior to joining CRG, Mr. Carter was a Partner at Palestra Capital, a New York-based hedge fund, where he focused on risk arbitrage, special situations, and distressed securities. Before joining Palestra in 1999, Mr. Carter was a High Yield Analyst at Furman Selz LLC (acquired by ING Barings), where he was responsible for coverage of healthcare-related high yield debt. Previously, Mr. Carter was an investment banking analyst in the Healthcare Group at Chemical Bank and a research assistant in the Mergers & Acquisitions Group of Morgan Stanley.

 

Mr. Carter received a Bachelor of Science in finance from The Pennsylvania State University in 1988. He received a Master of Arts degree in information science and systems in 1994 and an M.B.A. in 1996, both from Columbia University.

Collapse
Andrei Dorenbaum joined CRG in 2010. Previously, Mr. Dorenbaum was an assistant general counsel at Highland Capital Management, L.P., a registered investment advisor with over $20...

Andrei Dorenbaum

Managing Director - General Counsel

Andrei Dorenbaum joined CRG in 2010. Previously, Mr. Dorenbaum was an assistant general counsel at Highland Capital Management, L.P., a registered investment advisor with over $20 billion under management. While at Highland Capital, Mr. Dorenbaum completed over $2 billion in negotiated investments and structured derivative financing arrangements. Prior to Highland Capital, Mr. Dorenbaum acted as a Managing Director at NASD/NASDAQ/AMEX, overseeing the Corporate Ventures group that was responsible for direct investments in financial services companies. Previously, Mr. Dorenbaum was a corporate attorney with Baker & McKenzie.

 

Mr. Dorenbaum received a B.A. (magna cum laude) in applied economics and J.D. (cum laude) both from the University of Michigan. He also earned an LL.M. from Georgetown University School of Law.

Collapse
Garth Monroe joined CRG as Chief Financial Officer in March 2014. Prior to joining the firm, he was Vice President and CFO at both BioNano Genomics and Epocal, two early-stage...

Garth Monroe

Chief Financial Officer

Garth Monroe joined CRG as Chief Financial Officer in 2014. Prior to joining the firm, he was Vice President and CFO at both BioNano Genomics and Epocal, two early-stage biotechnology companies. In this capacity, he was responsible for finance, human resources, information technology, and supply chain. While at Epocal, he played an integral role in the $255 million sale of the company to Alere. Mr. Monroe started his career in the aerospace industry, working for United Technologies and JetBlue Airways; he also served in the U.S. Marine Corps.

 

Mr. Monroe is a CPA (inactive), and graduated summa cum laude from the University of Connecticut with a Bachelor of Science in Business Administration. He earned an MBA from the University of Virginia, Darden School of Business. 

Collapse
Scott Li joined CRG in 2015 and has been focused on the healthcare industry as an advisor, investor, and executive for over 15 years. Most recently, Mr. Li was an investment banker...

Scott Li

Principal

Scott Li joined CRG in 2015 and has been focused on the healthcare industry as an advisor, investor, and executive for over a decade.  Most recently, Mr. Li was an investment banker with Hammond Hanlon Camp LLC (“H2C”), where he advised on M&A engagements for clients, both investor-owned and not-for-profit, in various healthcare services sectors, including Tenet Healthcare, Bon Secours Health System, IASIS Healthcare and American Optical Services (in Chapter 11), among others.  Mr. Li’s previous investment banking experience also includes positions in the Life Sciences Investment Banking Group of Lazard and the North American M&A Group of J.P. Morgan.   

 

Prior to joining H2C, Mr. Li was the Chief Financial Officer of pingmd, a provider of an online communication platform for primary care physicians. In that role, he managed the company's financial functions, business development activities and interaction with investors.  Mr. Li was also previously an Associate with ABS Ventures, the venture capital arm of DB Capital Partners. 

  

Mr. Li received an AB in economics from Princeton University in 1997 and an MBA from the Wharton School at the University of Pennsylvania in 2004.

Collapse
Adam Whitehead joined CRG in 2016, bringing over 10 years of experience in asset allocation, manager due diligence and fundraising.

Adam Whitehead

Vice President

Adam Whitehead joined CRG in 2016, bringing over 10 years of experience in asset allocation, manager due diligence and fundraising. Previously, Mr. Whitehead was a senior investment analyst at Crestone Capital Advisors, a large multi-family office. Mr. Whitehead has held research and trading roles at Quantitative Equity Systems, Sovereign Wealth Management, Warwick Capital Management, The Bornhoft Group and Branch Banking & Trust.

 

Mr. Whitehead graduated from St. Andrews Presbyterian College, magna cum laude, in Laurinburg, North Carolina with a major in business (emphasis in finance and accounting).

Collapse
Cameron Hui joined CRG in 2012. Prior to CRG, Mr. Hui was an analyst with Stifel’s Healthcare Investment Banking Group. While at Stifel, Mr. Hui focused on capital markets and M&A...

Cameron Hui

Associate

Cameron Hui joined CRG in 2012. Prior to CRG, Mr. Hui was an analyst with Stifel’s Healthcare Investment Banking Group. While at Stifel, Mr. Hui focused on capital markets and M&A transactions for clients primarily in the Life Sciences and Medical Technology sectors. 

 

Mr. Hui graduated cum laude from the University of Southern California with a Bachelor of Science in Business Administration.

Collapse
"Zain Shekhani joined CRG in 2013. Prior to CRG, Mr. Shekhani was an analyst with Stifel's Healthcare Investment Banking Group. While at Stifel, Mr. Shekhani focused on capital markets...

Zain Shekhani

Associate

Zain Shekhani joined CRG in 2013. Prior to CRG, Mr. Shekhani was an analyst with Stifel's Healthcare Investment Banking Group. While at Stifel, Mr. Shekhani focused on capital markets and M&A transactions for clients primarily in the Life Sciences and Medical Technology sectors.

 

Mr. Shekhani graduated magna cum laude from the Stern School of Business at New York University with a Bachelor of Science in Finance and Economics.

Collapse
Kevin Reilly joined CRG in 2014. Previously, Mr. Reilly was an analyst with Stifel's Healthcare Investment Banking Group. At Stifel, Mr. Reilly focused on financing and advisory...

Kevin Reilly

Associate

Kevin Reilly joined CRG in 2014. Previously, Mr. Reilly was an analyst with Stifel's Healthcare Investment Banking Group. At Stifel, Mr. Reilly focused on financing and advisory transactions for clients primarily in the Life Sciences, Medical Technology, and Services sectors.

 

Mr. Reilly graduated from the Robert H. Smith School of Business at the University of Maryland with a Bachelor of Science in Finance and Information Systems.

Collapse
Kris Talgo joined CRG in 2015. Prior to CRG, Mr. Talgo was an analyst with Leerink Partners’ Investment Banking Group. While at Leerink, Mr. Talgo focused on M&A and capital market...

Kris Talgo

Analyst

Kris Talgo joined CRG in 2015. Prior to CRG, Mr. Talgo was an analyst with Leerink Partners’ Investment Banking Group. While at Leerink, Mr. Talgo focused on M&A and capital market transactions for clients in the Life Sciences, Services and Medical Technology sectors. 

 

Mr. Talgo graduated cum laude from Lehigh University with a Bachelor of Science in Finance and Accounting.

Collapse
Stan Twarog joined CRG in 2016. Previously, Mr. Twarog served in a financial operations role at Surgical Care Affiliates, a leading outpatient ambulatory surgical care company. Prior...

Stanley Twarog

Analyst

Stan Twarog joined CRG in 2016. Previously, Mr. Twarog served in a financial operations role at Surgical Care Affiliates, a leading outpatient ambulatory surgical care company. Prior to joining Surgical Care Affiliates, Mr. Twarog was an analyst at Hammond Hanlon Camp, a healthcare focused strategic advisory and investment banking firm.

 

Mr. Twarog graduated cum laude from Vanderbilt University with a B.A. in Economics.

Collapse
Noah Putter joined CRG in 2016. Prior to CRG, Mr. Putter was an analyst with Leerink Partners’ Investment Banking Group.

Noah Putter

Analyst

Noah Putter joined CRG in 2016. Prior to CRG, Mr. Putter was an analyst with Leerink Partners’ Investment Banking Group. While at Leerink, Mr. Putter focused on M&A and capital market transactions for clients in the Life Sciences, Services and Medical Technology sectors. 

 

Mr. Putter graduated with high distinction from the University of Michigan’s Ross School of Business with a Bachelor of Business Administration.

Collapse
Erica Palestrini joined CRG in February 2014. Prior to CRG, she worked for the Magic Circle firm, Allen & Overy Law Firm in Singapore, in their business development department as a...

Erica Palestrini

Operations Manager

Erica Palestrini joined CRG in February 2014. Prior to CRG, she worked for the Magic Circle firm, Allen & Overy Law Firm in Singapore, in their business development department as a Marketing Assistant/Events Coordinator.  Ms. Palestrini has held operational support positions with various international companies including Olswang Law Firm in London, and Air New Zealand in Auckland, New Zealand.

Collapse
Courtney Grobe joined CRG in June of 2005. Prior to joining CRG, Ms. Grobe worked as an audit professional at Deloitte & Touche.

Courtney Grobe

Director, Accounting & Controller

Courtney Grobe joined CRG in 2005. Prior to joining CRG, Ms. Grobe worked as an audit professional at Deloitte & Touche, where her two largest clients were in the manufacturing and healthcare industries.

 

Ms. Grobe graduated magna cum laude from Texas A&M University receiving a Bachelor of Business Administration, specializing in accounting. Ms. Grobe also earned a Masters degree in Accounting from Texas A&M University and is a CPA.

Collapse
Ted Stiefel joined CRG in 2014. He has been working in biotechnology for over 15 years. Prior to joining CRG, Mr. Stiefel was Controller at BioNano Genomics, working with Garth Monroe....

Ted Stiefel

Finance Manager

Ted Stiefel joined CRG in 2014. He has been working in biotechnology for over 15 years. Prior to joining CRG, Mr. Stiefel was Controller at BioNano Genomics, working with Garth Monroe. Mr. Stiefel was responsible for overseeing the accounting, finance, and purchasing functions. He played an integral part in scaling the company for rapid growth from development to an international commercial operation, and he assisted in several debt and equity financings. Previously, he held accounting positions at several other small to midsize biotechnology companies. 

 

Mr. Stiefel is a licensed CPA and has earned a Bachelor of Science in Biology from UC San Diego and an MBA from San Diego State University.

Collapse
Colin Eckersley joined CRG in 2014. Prior to joined CRG, Mr. Eckersley held an accounting position at a small sales company.

Colin Eckersley

Senior Accountant

Colin Eckersley joined CRG in 2014. Prior to joining CRG, Mr. Eckersley held an accounting position at a small sales company.

 

Mr. Eckersley graduated from the C.T. Bauer College of Business at the University of Houston with a Bachelor of Business Administration, specializing in accounting. Mr. Eckersley also earned a Masters degree in Accounting from the University of Houston and is working on becoming a CPA. 

Collapse
Stephanie Divin joined CRG in 2016. Prior to joining CRG, Stephanie worked as an assurance professional at PricewaterhouseCoopers.

Stephanie Divin

Senior Accountant

Stephanie Divin joined CRG in 2016. Prior to joining CRG, Stephanie worked as an assurance professional at PricewaterhouseCoopers. Stephanie was in the Private Client Service group with clients in higher education, healthcare and manufacturing.

 

Stephanie is a licensed CPA and graduated from the McCombs School of Business at the University of Texas with a Bachelors of Business Administration and a Masters in Professional Accountancy.

Collapse
Carolyn Cranor joined CRG at its formation in 2003 as Executive Assistant to Charles W. Tate, the Chairman and Founder of the Firm.

Carolyn Cranor

Executive Assistant to Charles Tate

Carolyn Cranor joined CRG at its formation in 2003 as Executive Assistant to Charles W. Tate, the Chairman and Founder of the Firm.  Prior to that, she was Mr. Tate’s Executive Assistant at Hicks, Muse, Tate and Furst Incorporated from 1996 to 2003.   In the past, Ms. Cranor has also held various H.R. management, office management and executive assistant positions with Gardner-Denver/Cooper Industries at its Dallas/Sunnyvale, Texas offices.

Collapse
Ashley Anderson joined CRG in 2016.

Ashley Anderson

Executive Assistant

Ashley Anderson joined CRG in 2016. Prior to joining CRG she was an executive assistant at JP Morgan. Mrs. Anderson supported  a team of bankers in the Investment Banking group. She has held similar roles as executive assistant at Bank of America and Capital One Bank.

 

Mrs. Anderson graduated from Texas State University in San Marcos, Texas. 

Collapse
Nicole Nesson joined CRG in 2015. Prior to joining CRG she was an executive support professional at Bank of Montreal.

Nicole Nesson

Administrative Assistant

Nicole Nesson joined CRG in 2015. Prior to joining CRG she was an executive support professional at Bank of Montreal. While at Bank of Montreal, Ms. Nesson supported top Directors and Managing Directors in the Investment Banking group. She has held similar roles as executive assistant to the CEO of Lasco Enterprises and as office manager of credit risk software firm, Triple Point Technology.  

 

Ms. Nesson attended Stephen F. Austin State University, College of Fine Arts.  

All
Collapse
Charles W. Tate is Chairman and Founder of CRG. He has over 40 years’ experience in investment banking, merchant banking, and private equity.

Charles Tate

Chairman and Founder

Charles W. Tate is Chairman and Founder of CRG. He has over 40 years’ experience in investment banking, merchant banking, and private equity. Prior to forming CRG, Mr. Tate was a Partner and Member of the Management Committee of Hicks, Muse, Tate & Furst Incorporated from 1991 until June 2002. After starting his career at Bank of America in New York, he worked at Morgan Stanley & Co. for 19 years, mostly as a Managing Director in the Mergers and Acquisitions Department.

 

Presently, Mr. Tate is Chair and Director of the Board of Directors for The Welch Foundation.  He is also a Life Member of The University of Texas Development Board and a Senior Member of The University Cancer Foundation Board of Visitors for M.D. Anderson Cancer Center and previously was a member of the Board of Visitors Executive Committee.  He also previously served as Chairman of The University of Texas Department of Biomedical Engineering External Advisory Committee, The University of Texas System Chancellor’s Technology Commercialization Advisory Cabinet and The University of Texas at Austin Office of the President Committee on Business Productivity and was Chairman of its Subcommittee on Technology Commercialization.

 

Mr. Tate received his B.B.A. from The University of Texas at Austin in 1968. He was inducted into The University of Texas at Austin McCombs School of Business Hall of Fame in 2003, was named Distinguished Alumnus of The University of Texas in 2007 and also received The University of Texas at Austin 2011-2012 Presidential Citation in recognition of his leadership, sustained commitment, and service to The University.

 

Additionally, Mr. Tate received his M.B.A. from Columbia University Graduate School of Business in 1972 and has been a Member of its Board of Overseers since 2001. 

Collapse
Nate Hukill is the President of CRG and Chairman of CRG’s investment committee and opened the firm’s Boulder office. Mr. Hukill joined CRG in 2009, bringing more than 16 years of...

Nate Hukill

President and Chairman of the Investment Committee

Nate Hukill is the President of CRG and Chairman of CRG’s investment committee and opened the firm’s Boulder office. Mr. Hukill joined CRG in 2009, bringing more than 16 years of investing experience. Prior to joining CRG, Mr. Hukill was a Portfolio Manager at Highland Capital, where he invested and managed approximately $4.5 billion in the healthcare, consumer products, and technology sectors. Mr. Hukill primarily focused on fixed income healthcare investments with superior risk-adjusted returns. Beginning in 2005, Mr. Hukill built a Royalty Bond portfolio with $348 million of invested capital, becoming one of the largest and most influential Royalty Bond investors in the industry. Before Highland Capital, Mr. Hukill co-founded a pharmaceutical-focused enterprise software company called OpenQ, Inc. He started his career as a credit investor at Salomon Smith Barney where he managed a portfolio of approximately $800 million.

 

Mr. Hukill graduated Phi Beta Kappa, summa cum laude from the University of Colorado at Boulder in 1999 with a Bachelor of Science in business administration. He received an M.B.A. from the Darden Graduate School of Business at the University of Virginia in 2005. Mr. Hukill is a former professional cyclist, who competed professionally in both North America and Europe, including more than 30 first-place finishes. He previously was a member of the Board of Directors for Epocal, Inc., Complete Genomics, and OpenQ.

 

Boards and Service

 

  • 2014 to Present – AFT Pharmaceuticals, Board of Directors
  • 2007 to 2009 – Epocal, Inc., Board of Directors
  • 2007 to 2009 – Complete Genomics, Board of Directors
  • 2003 to 2005 – OpenQ, Board of Directors
Collapse
Luke Düster has more than 16 years of experience as both an advisor and investor in high growth companies. Since joining CRG in 2009, Mr. Düster has helped finance healthcare...

Luke Düster

Managing Director

Luke Düster has more than 16 years of experience as both an advisor and investor in high growth companies.  Since joining CRG in 2009, Mr. Düster has helped finance healthcare companies across a wide range of product technologies and therapeutic areas.  He has led investments in companies such as TriVascular, Tandem Diabetes, Nevro Corp., Astute Medical, Good Start Genetics, Nanostring Technologies and others.  Prior to CRG, Mr. Düster was a Vice President at Harris Williams & Co., where he advised private equity and corporate clients across a broad range of M&A assignments.  Mr. Düster also held investment banking roles at the Wallach Company, a regional investment banking boutique, and at the Nord Companies, a healthcare advisory firm.

 

Mr. Düster received a bachelor’s degree from the University of Colorado at Boulder in 1997, where he graduated summa cum laude. He received an MBA with honors from the Wharton School at the University of Pennsylvania in 2004.

Collapse
Michael Weinmann joined CRG in 2009 and has 15 years of capital markets and investing experience. Mr. Weinmann is a member of CRG’s investment committee and opened the firm’s New...

Mike Weinmann

Managing Director

Michael Weinmann joined CRG in 2009 and has 15 years of capital markets and investing experience. Mr. Weinmann is a member of CRG’s investment committee and opened the firm’s New York office. Previously, Mr. Weinmann worked as an Executive Director in Morgan Stanley’s Global Capital Markets division, specializing in structured debt financings and intellectual property monetizations. Mr. Weinmann was a co-developer of the Pharmaceutical Royalty Monetization Asset (Royalty Bond) product and sourced, structured and marketed the industry’s first 14 Royalty Bond transactions. Prior to joining CRG, Mr. Weinmann was responsible for $3.3 billion of healthcare royalty monetizations, including 14 Royalty Bonds and 3 Traditional Royalty Purchases. He joined Morgan Stanley in 1999 and had a leading role in the structuring of debt financings involving pharmaceutical royalties, infrastructure assets, aircraft, rolling stock, ships, power generation facilities, and real estate. 

 

Mr. Weinmann received a Bachelor of Science in chemical engineering in 1999 from the Johns Hopkins University, graduating first in a class of 770.

 

Boards and Service

 

  • 2014 to Present – AFT Pharmaceuticals, Board Observer
  • 2010 to Present – Johns Hopkins Homewood Technology Commercialization, Advisory Board
Collapse
David Carter joined CRG in 2003 and has more than 20 years of investment experience. Prior to joining CRG, Mr. Carter was a Partner at Palestra Capital, a New York-based hedge fund,...

David Carter

Managing Director

David Carter joined CRG in 2003 and has more than 20 years of investment experience. Prior to joining CRG, Mr. Carter was a Partner at Palestra Capital, a New York-based hedge fund, where he focused on risk arbitrage, special situations, and distressed securities. Before joining Palestra in 1999, Mr. Carter was a High Yield Analyst at Furman Selz LLC (acquired by ING Barings), where he was responsible for coverage of healthcare-related high yield debt. Previously, Mr. Carter was an investment banking analyst in the Healthcare Group at Chemical Bank and a research assistant in the Mergers & Acquisitions Group of Morgan Stanley.

 

Mr. Carter received a Bachelor of Science in finance from The Pennsylvania State University in 1988. He received a Master of Arts degree in information science and systems in 1994 and an M.B.A. in 1996, both from Columbia University.

Collapse
Andrei Dorenbaum joined CRG in 2010. Previously, Mr. Dorenbaum was an assistant general counsel at Highland Capital Management, L.P., a registered investment advisor with over $20...

Andrei Dorenbaum

Managing Director - General Counsel

Andrei Dorenbaum joined CRG in 2010. Previously, Mr. Dorenbaum was an assistant general counsel at Highland Capital Management, L.P., a registered investment advisor with over $20 billion under management. While at Highland Capital, Mr. Dorenbaum completed over $2 billion in negotiated investments and structured derivative financing arrangements. Prior to Highland Capital, Mr. Dorenbaum acted as a Managing Director at NASD/NASDAQ/AMEX, overseeing the Corporate Ventures group that was responsible for direct investments in financial services companies. Previously, Mr. Dorenbaum was a corporate attorney with Baker & McKenzie.

 

Mr. Dorenbaum received a B.A. (magna cum laude) in applied economics and J.D. (cum laude) both from the University of Michigan. He also earned an LL.M. from Georgetown University School of Law.

Collapse
Scott Li joined CRG in 2015 and has been focused on the healthcare industry as an advisor, investor, and executive for over 15 years. Most recently, Mr. Li was an investment banker...

Scott Li

Principal

Scott Li joined CRG in 2015 and has been focused on the healthcare industry as an advisor, investor, and executive for over a decade.  Most recently, Mr. Li was an investment banker with Hammond Hanlon Camp LLC (“H2C”), where he advised on M&A engagements for clients, both investor-owned and not-for-profit, in various healthcare services sectors, including Tenet Healthcare, Bon Secours Health System, IASIS Healthcare and American Optical Services (in Chapter 11), among others.  Mr. Li’s previous investment banking experience also includes positions in the Life Sciences Investment Banking Group of Lazard and the North American M&A Group of J.P. Morgan.   

 

Prior to joining H2C, Mr. Li was the Chief Financial Officer of pingmd, a provider of an online communication platform for primary care physicians. In that role, he managed the company's financial functions, business development activities and interaction with investors.  Mr. Li was also previously an Associate with ABS Ventures, the venture capital arm of DB Capital Partners. 

  

Mr. Li received an AB in economics from Princeton University in 1997 and an MBA from the Wharton School at the University of Pennsylvania in 2004.

Collapse
Adam Whitehead joined CRG in 2016, bringing over 10 years of experience in asset allocation, manager due diligence and fundraising.

Adam Whitehead

Vice President

Adam Whitehead joined CRG in 2016, bringing over 10 years of experience in asset allocation, manager due diligence and fundraising. Previously, Mr. Whitehead was a senior investment analyst at Crestone Capital Advisors, a large multi-family office. Mr. Whitehead has held research and trading roles at Quantitative Equity Systems, Sovereign Wealth Management, Warwick Capital Management, The Bornhoft Group and Branch Banking & Trust.

 

Mr. Whitehead graduated from St. Andrews Presbyterian College, magna cum laude, in Laurinburg, North Carolina with a major in business (emphasis in finance and accounting).

Collapse
Cameron Hui joined CRG in 2012. Prior to CRG, Mr. Hui was an analyst with Stifel’s Healthcare Investment Banking Group. While at Stifel, Mr. Hui focused on capital markets and M&A...

Cameron Hui

Associate

Cameron Hui joined CRG in 2012. Prior to CRG, Mr. Hui was an analyst with Stifel’s Healthcare Investment Banking Group. While at Stifel, Mr. Hui focused on capital markets and M&A transactions for clients primarily in the Life Sciences and Medical Technology sectors. 

 

Mr. Hui graduated cum laude from the University of Southern California with a Bachelor of Science in Business Administration.

Collapse
"Zain Shekhani joined CRG in 2013. Prior to CRG, Mr. Shekhani was an analyst with Stifel's Healthcare Investment Banking Group. While at Stifel, Mr. Shekhani focused on capital markets...

Zain Shekhani

Associate

Zain Shekhani joined CRG in 2013. Prior to CRG, Mr. Shekhani was an analyst with Stifel's Healthcare Investment Banking Group. While at Stifel, Mr. Shekhani focused on capital markets and M&A transactions for clients primarily in the Life Sciences and Medical Technology sectors.

 

Mr. Shekhani graduated magna cum laude from the Stern School of Business at New York University with a Bachelor of Science in Finance and Economics.

Collapse
Kevin Reilly joined CRG in 2014. Previously, Mr. Reilly was an analyst with Stifel's Healthcare Investment Banking Group. At Stifel, Mr. Reilly focused on financing and advisory...

Kevin Reilly

Associate

Kevin Reilly joined CRG in 2014. Previously, Mr. Reilly was an analyst with Stifel's Healthcare Investment Banking Group. At Stifel, Mr. Reilly focused on financing and advisory transactions for clients primarily in the Life Sciences, Medical Technology, and Services sectors.

 

Mr. Reilly graduated from the Robert H. Smith School of Business at the University of Maryland with a Bachelor of Science in Finance and Information Systems.

Collapse
Kris Talgo joined CRG in 2015. Prior to CRG, Mr. Talgo was an analyst with Leerink Partners’ Investment Banking Group. While at Leerink, Mr. Talgo focused on M&A and capital market...

Kris Talgo

Analyst

Kris Talgo joined CRG in 2015. Prior to CRG, Mr. Talgo was an analyst with Leerink Partners’ Investment Banking Group. While at Leerink, Mr. Talgo focused on M&A and capital market transactions for clients in the Life Sciences, Services and Medical Technology sectors. 

 

Mr. Talgo graduated cum laude from Lehigh University with a Bachelor of Science in Finance and Accounting.

Collapse
Stan Twarog joined CRG in 2016. Previously, Mr. Twarog served in a financial operations role at Surgical Care Affiliates, a leading outpatient ambulatory surgical care company. Prior...

Stanley Twarog

Analyst

Stan Twarog joined CRG in 2016. Previously, Mr. Twarog served in a financial operations role at Surgical Care Affiliates, a leading outpatient ambulatory surgical care company. Prior to joining Surgical Care Affiliates, Mr. Twarog was an analyst at Hammond Hanlon Camp, a healthcare focused strategic advisory and investment banking firm.

 

Mr. Twarog graduated cum laude from Vanderbilt University with a B.A. in Economics.

Collapse
Noah Putter joined CRG in 2016. Prior to CRG, Mr. Putter was an analyst with Leerink Partners’ Investment Banking Group.

Noah Putter

Analyst

Noah Putter joined CRG in 2016. Prior to CRG, Mr. Putter was an analyst with Leerink Partners’ Investment Banking Group. While at Leerink, Mr. Putter focused on M&A and capital market transactions for clients in the Life Sciences, Services and Medical Technology sectors. 

 

Mr. Putter graduated with high distinction from the University of Michigan’s Ross School of Business with a Bachelor of Business Administration.

Collapse
Erica Palestrini joined CRG in February 2014. Prior to CRG, she worked for the Magic Circle firm, Allen & Overy Law Firm in Singapore, in their business development department as a...

Erica Palestrini

Operations Manager

Erica Palestrini joined CRG in February 2014. Prior to CRG, she worked for the Magic Circle firm, Allen & Overy Law Firm in Singapore, in their business development department as a Marketing Assistant/Events Coordinator.  Ms. Palestrini has held operational support positions with various international companies including Olswang Law Firm in London, and Air New Zealand in Auckland, New Zealand.

Investment Team
Collapse
Andrei Dorenbaum joined CRG in 2010. Previously, Mr. Dorenbaum was an assistant general counsel at Highland Capital Management, L.P., a registered investment advisor with over $20...

Andrei Dorenbaum

Managing Director - General Counsel

Andrei Dorenbaum joined CRG in 2010. Previously, Mr. Dorenbaum was an assistant general counsel at Highland Capital Management, L.P., a registered investment advisor with over $20 billion under management. While at Highland Capital, Mr. Dorenbaum completed over $2 billion in negotiated investments and structured derivative financing arrangements. Prior to Highland Capital, Mr. Dorenbaum acted as a Managing Director at NASD/NASDAQ/AMEX, overseeing the Corporate Ventures group that was responsible for direct investments in financial services companies. Previously, Mr. Dorenbaum was a corporate attorney with Baker & McKenzie.

 

Mr. Dorenbaum received a B.A. (magna cum laude) in applied economics and J.D. (cum laude) both from the University of Michigan. He also earned an LL.M. from Georgetown University School of Law.

Collapse
Garth Monroe joined CRG as Chief Financial Officer in March 2014. Prior to joining the firm, he was Vice President and CFO at both BioNano Genomics and Epocal, two early-stage...

Garth Monroe

Chief Financial Officer

Garth Monroe joined CRG as Chief Financial Officer in 2014. Prior to joining the firm, he was Vice President and CFO at both BioNano Genomics and Epocal, two early-stage biotechnology companies. In this capacity, he was responsible for finance, human resources, information technology, and supply chain. While at Epocal, he played an integral role in the $255 million sale of the company to Alere. Mr. Monroe started his career in the aerospace industry, working for United Technologies and JetBlue Airways; he also served in the U.S. Marine Corps.

 

Mr. Monroe is a CPA (inactive), and graduated summa cum laude from the University of Connecticut with a Bachelor of Science in Business Administration. He earned an MBA from the University of Virginia, Darden School of Business. 

Collapse
Courtney Grobe joined CRG in June of 2005. Prior to joining CRG, Ms. Grobe worked as an audit professional at Deloitte & Touche.

Courtney Grobe

Director, Accounting & Controller

Courtney Grobe joined CRG in 2005. Prior to joining CRG, Ms. Grobe worked as an audit professional at Deloitte & Touche, where her two largest clients were in the manufacturing and healthcare industries.

 

Ms. Grobe graduated magna cum laude from Texas A&M University receiving a Bachelor of Business Administration, specializing in accounting. Ms. Grobe also earned a Masters degree in Accounting from Texas A&M University and is a CPA.

Collapse
Ted Stiefel joined CRG in 2014. He has been working in biotechnology for over 15 years. Prior to joining CRG, Mr. Stiefel was Controller at BioNano Genomics, working with Garth Monroe....

Ted Stiefel

Finance Manager

Ted Stiefel joined CRG in 2014. He has been working in biotechnology for over 15 years. Prior to joining CRG, Mr. Stiefel was Controller at BioNano Genomics, working with Garth Monroe. Mr. Stiefel was responsible for overseeing the accounting, finance, and purchasing functions. He played an integral part in scaling the company for rapid growth from development to an international commercial operation, and he assisted in several debt and equity financings. Previously, he held accounting positions at several other small to midsize biotechnology companies. 

 

Mr. Stiefel is a licensed CPA and has earned a Bachelor of Science in Biology from UC San Diego and an MBA from San Diego State University.

Collapse
Colin Eckersley joined CRG in 2014. Prior to joined CRG, Mr. Eckersley held an accounting position at a small sales company.

Colin Eckersley

Senior Accountant

Colin Eckersley joined CRG in 2014. Prior to joining CRG, Mr. Eckersley held an accounting position at a small sales company.

 

Mr. Eckersley graduated from the C.T. Bauer College of Business at the University of Houston with a Bachelor of Business Administration, specializing in accounting. Mr. Eckersley also earned a Masters degree in Accounting from the University of Houston and is working on becoming a CPA. 

Collapse
Stephanie Divin joined CRG in 2016. Prior to joining CRG, Stephanie worked as an assurance professional at PricewaterhouseCoopers.

Stephanie Divin

Senior Accountant

Stephanie Divin joined CRG in 2016. Prior to joining CRG, Stephanie worked as an assurance professional at PricewaterhouseCoopers. Stephanie was in the Private Client Service group with clients in higher education, healthcare and manufacturing.

 

Stephanie is a licensed CPA and graduated from the McCombs School of Business at the University of Texas with a Bachelors of Business Administration and a Masters in Professional Accountancy.

Collapse
Ashley Anderson joined CRG in 2016.

Ashley Anderson

Executive Assistant

Ashley Anderson joined CRG in 2016. Prior to joining CRG she was an executive assistant at JP Morgan. Mrs. Anderson supported  a team of bankers in the Investment Banking group. She has held similar roles as executive assistant at Bank of America and Capital One Bank.

 

Mrs. Anderson graduated from Texas State University in San Marcos, Texas. 

Collapse
Nicole Nesson joined CRG in 2015. Prior to joining CRG she was an executive support professional at Bank of Montreal.

Nicole Nesson

Administrative Assistant

Nicole Nesson joined CRG in 2015. Prior to joining CRG she was an executive support professional at Bank of Montreal. While at Bank of Montreal, Ms. Nesson supported top Directors and Managing Directors in the Investment Banking group. She has held similar roles as executive assistant to the CEO of Lasco Enterprises and as office manager of credit risk software firm, Triple Point Technology.  

 

Ms. Nesson attended Stephen F. Austin State University, College of Fine Arts.  

Legal, Finance & Compliance
Collapse
Harry Loveys helped found CRG in 2003, bringing more than 25 years of experience in the pharmaceutical industry. Before CRG, Mr. Loveys was the Executive Vice President of Drug Royalty...

Harry Loveys

Senior Consultant

Harry Loveys helped found CRG in 2003, bringing more than 25 years of experience in the pharmaceutical industry. Before CRG, Mr. Loveys was the Executive Vice President of Drug Royalty Corporation, the first public royalty investment company. Mr. Loveys joined Drug Royalty as a Senior Vice President in 1995. During his tenure, Drug Royalty invested CAD $101 million in healthcare royalty transactions with inventors, universities, and biotechnology and pharmaceutical companies. From 1989 to 1995, Mr. Loveys was an Executive Vice President of the Upjohn Company of Canada, overseeing domestic sales and marketing, business development, medical, regulatory, government, and professional affairs.

 

Mr. Loveys received a Bachelor of Commerce from Acadia University in 1969.

Collapse
Phil Houston is a nationally recognized authority on deception detection, critical interviewing, and elicitation. His 25 year career with the Central Intelligence Agency was...

Phil Houston

Senior Advisor

Phil Houston is a nationally recognized authority on deception detection, critical interviewing, and elicitation. His 25 year career with the Central Intelligence Agency was highlighted by his service as a senior member of the Office of Security. In that capacity he conducted thousands of interviews and interrogations for the CIA and other federal agencies, both as an investigator and as a polygraph examiner. He is credited with developing a detection of deception methodology currently employed throughout the U.S. intelligence and federal law enforcement communities. Mr. Houston introduced the detection of deception methodology to the corporate world with the co-founding of Business Intelligence Advisors, where he served as Executive Vice President.

 

Mr. Houston holds a B.A. in Political Science from East Carolina University in Greenville, N.C.

Collapse
Mr. Termeer was appointed president of Genzyme in 1983, became its chief executive officer in 1985 and chairman in 1988.

Henri Termeer

Senior Advisor

Mr. Termeer was appointed president of Genzyme in 1983, became its chief executive officer in 1985 and chairman in 1988.  He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care.  Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, a director of Massachusetts General Hospital, board member of Partners HealthCare and a member of the Board of Fellows of Harvard Medical School. 

 

He sits on the boards of Project Hope, Biotechnology Industry Organization (BIO), New England Healthcare Institute (NEHI), Boston Ballet, Museum of Science and WGBH.  He also serves on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Moderna Therapeutics, ProQR Therapeutics and Verastem, Inc..  Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden Business School at the University of Virginia. 

Collapse
Mark McClellan is the Director of the Robert J Margolis Center for Health Policy and the Margolis Professor of Business, Medicine and Health Policy at Duke University.

Mark McClellan, MD, PhD

Senior Advisor

Mark McClellan is the Director of the Robert J Margolis Center for Health Policy and the Margolis Professor of Business, Medicine and Health Policy at Duke University. Prior to this, Mark was a Senior Fellow and Director of the Initiatives on Value and Innovation in Health Care at the Brookings Institution. His work focuses on strategies and policy reforms to improve health care, including such areas as accountable care, better evidence from real-world practice, and more effective drug and device innovation. A doctor and economist by training, he also has a highly distinguished record in public service and in academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, Medicare and Medicaid payment reforms, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care.

 

Dr. McClellan is the founding chair and a current board member of the Reagan-Udall Foundation for the FDA, is co-chair of the Quality Alliance Steering Committee, chairs the National Quality Forum’s partnership on clinician quality measurement, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He has also served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and as Deputy Assistant Secretary for Economic Policy at the Department of the Treasury.  He was previously an associate professor of economics and medicine with tenure at Stanford University, and has twice received the Kenneth Arrow Award for Outstanding Research in Health Economics.

Collapse
Harlan F. Weisman, M.D. is the founder and Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government...

Harlan Weisman, MD

Senior Advisor

Harlan F. Weisman, M.D. is the founder and Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing successful strategies for driving innovation in healthcare products and services. He is co-founder, Board Director and Chief Scientific Officer for Mycrobiomics, Inc. and Executive Chairman of 3DBio Corp.  He is also on the board of directors of ControlRad Systems, Inc and Hutchison Biofilm Medical Solutions Ltd, and is an advisor to the Israel Biotechnology Fund, the Johns Hopkins Institute for Basic Biomedical Sciences, Memorial Sloan Kettering Cancer Center and BioMotiv, a medical product accelerator company.

 

Previously, Dr. Weisman was Chairman and CEO of Coronado Biosciences, Inc., a company focused on developing treatments for immune mediated inflammatory disorders.  Prior to Coronado, he served over 20 years as a senior executive at Johnson & Johnson including as Chief Science and Technology Officer of the J&J Medical Devices Group, Company Group Chairman, J&J Pharmaceutical Research & Development, President of Centocor R&D and also served on the board of directors of J&J Development Corporation (JJDC). Before joining industry, Dr. Weisman was Assistant Professor of Medicine and Director of the Experimental Cardiac Pathology Laboratory at the Johns Hopkins University School of Medicine, and Consultant Cardiologist at Johns Hopkins Hospital.

 

Dr. Weisman has authored more than 100 articles and book chapters about cardiovascular disease, medical product development, healthcare policy and organizational development. He is a frequent invited speaker at international meetings on medical innovation, health policy and product development strategy.

Advisory